Pirenzepine: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
 
Line 1: Line 1:
{{drugbox | IUPAC_name =11-[(4-Methylpiperazin-1yl)acetyl]6,11-dihydro-5''H''-pyrido[2,3-''b''][1,4]benzodiazepin-6-on| image = Pirenzepine.png | width = 221 | CAS_number = 28797-61-7 | ATC_prefix = A02 | ATC_suffix = BX03 | ATC_supplemental = | PubChem = 4848 | DrugBank = APRD00515 | C=19 | H=21 | N=5 | O=2 | molecular_weight = 351.403 g/mol | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | pregnancy_category = | legal_status = | routes_of_administration = }}
{{drugbox | IUPAC_name =11-[(4-Methylpiperazin-1yl)acetyl]6,11-dihydro-5''H''-pyrido[2,3-''b''][1,4]benzodiazepin-6-on| image =Pirenzepine.png | width = 221 | CAS_number = 28797-61-7 | ATC_prefix = A02 | ATC_suffix = BX03 | ATC_supplemental = | PubChem = 4848 | DrugBank = APRD00515 | C=19 | H=21 | N=5 | O=2 | molecular_weight = 351.403 g/mol | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | pregnancy_category = | legal_status = | routes_of_administration = }}
__Notoc__
__Notoc__
{{SI}}
{{SI}}

Latest revision as of 14:47, 9 April 2015

Pirenzepine
Clinical data
ATC code
Identifiers
CAS Number
PubChem CID
DrugBank
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC19H21N5O2
Molar mass351.403 g/mol

WikiDoc Resources for Pirenzepine

Articles

Most recent articles on Pirenzepine

Most cited articles on Pirenzepine

Review articles on Pirenzepine

Articles on Pirenzepine in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Pirenzepine

Images of Pirenzepine

Photos of Pirenzepine

Podcasts & MP3s on Pirenzepine

Videos on Pirenzepine

Evidence Based Medicine

Cochrane Collaboration on Pirenzepine

Bandolier on Pirenzepine

TRIP on Pirenzepine

Clinical Trials

Ongoing Trials on Pirenzepine at Clinical Trials.gov

Trial results on Pirenzepine

Clinical Trials on Pirenzepine at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Pirenzepine

NICE Guidance on Pirenzepine

NHS PRODIGY Guidance

FDA on Pirenzepine

CDC on Pirenzepine

Books

Books on Pirenzepine

News

Pirenzepine in the news

Be alerted to news on Pirenzepine

News trends on Pirenzepine

Commentary

Blogs on Pirenzepine

Definitions

Definitions of Pirenzepine

Patient Resources / Community

Patient resources on Pirenzepine

Discussion groups on Pirenzepine

Patient Handouts on Pirenzepine

Directions to Hospitals Treating Pirenzepine

Risk calculators and risk factors for Pirenzepine

Healthcare Provider Resources

Symptoms of Pirenzepine

Causes & Risk Factors for Pirenzepine

Diagnostic studies for Pirenzepine

Treatment of Pirenzepine

Continuing Medical Education (CME)

CME Programs on Pirenzepine

International

Pirenzepine en Espanol

Pirenzepine en Francais

Business

Pirenzepine in the Marketplace

Patents on Pirenzepine

Experimental / Informatics

List of terms related to Pirenzepine

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Pirenzepine (marketed by Merck Marker under the trade-name Gastrozepin) is used in the treatment of peptic ulcers, as it reduces gastric acid secretion and reduces muscle spasm. It is in a class of drugs known as Muscarinic receptor antagonists - acetylcholine being the neurotransmitter of the parasympathetic nervous system which initiates the rest-and-digest state (as opposed to fight-or-flight), the result being an increase in gastric motility and digestion. It has no effects on the brain and spinal cord as it cannot diffuse through the blood-brain barrier.

Pirenzepine has been investigated for use in myopia control.[1]

References

  1. Czepita D (2005). "Fundamentals of modern treatment of myopia". Ann Acad Med Stetin. 51 (2): 5–9. PMID 16519089.

Template:Pharma-stub Template:Drugs for peptic ulcer and GORD